Marksans Pharma | Business Upturn

Latest Articles

Marksans Pharma gets final USFDA approval for Loperamide Hydrochloride Tablets

Corporates · Nov 19, 2025

blank

Marksans Pharma secures UK MHRA approval for 250 mg and 500 mg Mefenamic Acid

Corporates · Nov 17, 2025

blank

Marksans Pharma’s UK subsidiary Relonchem gets MHRA approval for Exemestane 25mg Tablets

Corporates · Nov 5, 2025

blank

Marksans Pharma’s UK Subsidiary Relonchem secures marketing authorization for Moxonidine tablets from UK MHRA

Corporates · Sep 23, 2025

blank

Marksans Pharma’s UK subsidiary Relonchem secures marketing authorization from MHRA for Metformin tablets

Corporates · Aug 18, 2025

blank

Marksans Pharma shares drop 13% as Q1 net profit falls 34.3% YoY to Rs 58.3 crore, revenue down 5% YoY

Stock Market · Aug 12, 2025

blank

Marksans Pharma subsidiary gets USFDA final approval for 20 mg Omeprazole Delayed-Release Tablets

Corporates · Aug 8, 2025

blank

Marksans Pharma receives EIR from USFDA for Time-Cap Labs facility

Corporates · Jun 30, 2025

blank

Marksans Pharma’s subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution

Corporates · May 30, 2025

blank

Marksans Pharma’s subsidiary receives one USFDA observation after cGMP inspection at New York facility

Corporates · Apr 28, 2025

blank

Marksans Pharma’s Goa facility gets Australian TGA approval for Solid Dosage manufacturing

Corporates · Mar 20, 2025

blank

Marksans Pharma’s subsidiary Relonchem receives marketing authorization from UK MHRA for Baclofen 10 mg tablets

Corporates · Mar 19, 2025

blank

Marksans Pharma’s subsidiary Relonchem gets UK approval for Ibuprofen and Paracetamol tablets

Corporates · Feb 25, 2025

blank

Marksans Pharma shares jump 2% following USFDA approval for Loratadine Tablets USP 10 mg

Stock Market · Nov 22, 2024

blank

Marksans Pharma receives USFDA approval for Loratadine Tablets USP 10 mg

Corporates · Nov 22, 2024

By Aditya Bhagchandani

Showing 15 of 18 articles